The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice
Open accessAbstract
Background and Purpose: Naringenin, a flavonoid compound with strong anti‐inflammatory activity, attenuated non‐alcoholic fatty liver disease (NAFLD) induced by a methionine‐choline deficient (MCD) diet in mice. However, the mechanisms underlying this suppression of inflammation and NAFLD remain unknown. Experimental Approach: WT and NLRP3−/− mice were fed with MCD diet for 7 days to induce NAFLD and were given naringenin by gavage at the same time. in vitro experiments used HepG2 cells, primary hepatocytes, and Kupffer cells (KCs) stimulated by LPS or LPS plus oleic acid (OA). Key Results: Treating WT mice with naringenin (100 mg·kg−1·day−1) attenuated hepatic lipid accumulation and inflammation in the livers of mice given the MCD diet. NLRP3−/− mice showed less hepatic lipid accumulation than WT mice, but naringenin did not ameliorate hepatic lipid accumulation further in NLRP3−/− mice. Treating the HepG2 cells with naringenin or NLRP3 inhibitor MCC950 reduced lipid accumulation. Naringenin inhibited activation of the NLRP3/NF‐κB pathway stimulated by OA together with LPS. In KCs isolated from WT mice, naringenin inhibited NLRP3 expression. Naringenin also inhibited lipid deposition, NLRP3 and IL‐1β expression in WT hepatocytes but was not effective in NLRP3−/− hepatocytes. After re‐expressing NLRP3 in NLRP3−/− hepatocytes by adenovirus, the anti‐lipid deposition effect of naringenin was restored. Conclusion and Implications: Naringenin prevented NAFLD via down‐regulating the NLRP3/NF‐κB signalling pathway both in KCs and in hepatocytes, thus attenuating inflammation in the mice livers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
NF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14153 · Cited by 1,338 · cited 1×
“The data and statistical analysis in this study comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018).”
MethodMcGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14112 · Cited by 891
NLRP3 inflammasome and its inhibitors: a review
Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., & Liu, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00262 · Cited by 836
Wang, Y., Xu, C.-F., Liu, Y.-J., Mao, Y.-F., Lv, Z., Li, S.-Y., Zhu, X.-Y., & Jiang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477112 · Cited by 825
Alam, M. A., Subhan, N., Rahman, M. M., Uddin, S. J., Reza, H. M., & Sarker, S. D. (2014) · Advances in Nutrition · doi:10.3945/an.113.005603 · Cited by 788
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome
Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M., & Lustig, R. H. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.41 · Cited by 771
Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.008 · Cited by 732
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Inflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
Inflammasomes in liver diseases
Szabo, G., & Csak, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 495
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., & Tiribelli, C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.003 · Cited by 425
IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult
Xiao, H., Li, H., Wang, J.-J., Zhang, J.-S., Shen, J., An, X.-B., Zhang, C.-C., Wu, J.-M., Song, Y., Wang, X.-Y., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx261 · Cited by 305
Self-citationNaringenin as a potential immunomodulator in therapeutics
Zeng, W., Jin, L., Zhang, F., Zhang, C., & Liang, W. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.002 · Cited by 305
Mulvihill, E. E., Allister, E. M., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Markle, J. M., Hegele, R. A., & Huff, M. W. (2009) · Diabetes · doi:10.2337/db09-0634 · Cited by 297
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Han, C. Y., Rho, H. S., Kim, A., Kim, T. H., Jang, K., Jun, D. W., Kim, J. W., Kim, B., & Kim, S. G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.068 · Cited by 232
NLRP3 inflammasome expression is driven by NF-κB in cultured hepatocytes
Boaru, S. G., Borkham-Kamphorst, E., Van de Leur, E., Lehnen, E., Liedtke, C., & Weiskirchen, R. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.029 · Cited by 201
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14751 · Cited by 192
Dong, B., Zhou, Y., Wang, W., Scott, J., Kim, K., Sun, Z., Guo, Q., Lu, Y., Gonzales, N. M., Wu, H., et al. (2020) · Hepatology · doi:10.1002/hep.30937 · Cited by 180
Mulvihill, E. E., Assini, J. M., Sutherland, B. G., DiMattia, A. S., Khami, M., Koppes, J. B., Sawyez, C. G., Whitman, S. C., & Huff, M. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.201095 · Cited by 164
Aldosari, D. I., Ahmed, M. M., Al-Rejaie, S. S., Alhomida, A. S., & Ola, M. S. (2017) · Nutrients · doi:10.3390/nu9101161 · Cited by 155
Burke, A. C., Sutherland, B. G., Telford, D. E., Morrow, M. R., Sawyez, C. G., Edwards, J. Y., Drangova, M., & Huff, M. W. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m087387 · Cited by 129
Naringenin Ameliorates Acute Inflammation by Regulating Intracellular Cytokine Degradation
Jin, L., Zeng, W., Zhang, F., Zhang, C., & Liang, W. P. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602016 · Cited by 113
Naringenin and Atherosclerosis: A Review of Literature
Orhan, İ. E., Nabavi, S. F., Daglia, M., Tenore, G. C., Mansouri, K., & Nabavi, S. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141202110216 · Cited by 109
Coulon, S., Legry, V., Heindryckx, F., Steenkiste, C. V., Casteleyn, C. R., Olievier, K., Libbrecht, L. J., Carmeliet, P., Jonckx, B., Stassen, J., et al. (2013) · Hepatology · doi:10.1002/hep.26219 · Cited by 103
Gianfrancesco, M. A., Dehairs, J., L’homme, L., Herinckx, G., Esser, N., Jansen, O., Habraken, Y., Lassence, C., Swinnen, J. V., Rider, M. H., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.04.001 · Cited by 99
Rex, J., Lutz, A., Faletti, L. E., Albrecht, U., Thomas, M., Bode, J. G., Borner, C., Sawodny, O., & Merfort, I. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00117 · Cited by 88
Zhao, M., Li, C. R., Shen, F., Wang, M., Jia, N., & Wang, C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4772 · Cited by 84
Ke, J., Banh, T., Hsiao, Y., Cole, R. M., Straka, S. R., Yee, L. D., & Belury, M. A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600934 · Cited by 64
Naringenin inhibits spinal cord injury-induced activation of neutrophils through miR-223
Shi, L., Tang, P., Zhang, W., Zhao, Y.-P., Zhang, L., & Zhang, H. (2016) · Gene · doi:10.1016/j.gene.2016.07.037 · Cited by 55
Isolation of Liver Kupffer Cells
Froh, M., Konno, A., & Thurman, R. G. (2002) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx1404s14 · Cited by 51
Pallayová, M., & Taheri, S. (2014) · Clinical Obesity · doi:10.1111/cob.12068 · Cited by 43
Cited by
Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe−/−mice: role of SIRT1
Hua, Y. Q., Zeng, Y., Xu, J., & Xu, X. L. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153412 · Cited by 137
The macrophage polarization in inflammatory dermatosis and its potential drug candidates
Sun, Q., Hu, S., Lou, Z., & Gao, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114469 · Cited by 66
Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1
Hu, P., Shan, X., Dong, H., Yu, S., Wang, B., Xiong, H., Ji, Z., Jing, W., Cui, Y., Li, Z., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115426 · Cited by 12
Metadata
- Authors
- Wang, Q., Ou, Y., Hu, G., Wen, C., Yue, S., Chen, C., Xu, L., Xie, J., Dai, H., Xiao, H., Zhang, Y., & Qi, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2020-01-30
- Volume
- 177
- Issue
- 8
- Pages
- 1806-1821
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2990473002
- Cited by
- 309
- References
- 40
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
